What's Hot
View all perspectives
Dr. John Cush RheumNow
1 year ago
#ACR23 Daily Recap - MONDAY
https://t.co/PsCTB36BvR https://t.co/6cBHwm1ubY
Dr. John Cush RheumNow
1 year ago
The Heart of Lupus
During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease. The ones that caught my eye included...
https://t.co/5Qk2fF3nlA #ACR23 https://t.co/Rja7K44BUf
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
L16 @ #ACR23
⭐️Can you discontinue glucocorticoids (GC) & immunosuppressive agent (IM) in stable IgG4-RD (clinically quiescent for at least 12 mo)?
➡️146 pts followed for 18 mo:
👉Group 1: withdraw GC+IM
vs
👉Group 2: withdraw GC… https://t.co/j77xYm9qSN https://t.co/72IwBeEwv9
Richard Conway
1 year ago
Peng et al. 146 IgG4-RD in remission on immunomodulators+GC. 18 month follow-up. Withdraw IM+GC - 52% flare. Withdraw GC + continue IM 14.2% flare. Continue both 12.2% flare. Clear message that ongoing IM is the way Abstr#L16 #ACR23 #ACRbest @RheumNow https://t.co/3CAQhyTYqq https://t.co/qr1GOSvJYg
Eric Dein
1 year ago
L16 #ACR23 @RheumNow
W/d of Immunosuppr and Low-dose steroid in IgG4RD
Gr1: W/d GC+IM, G2: IM alone, G3: Maintain
Relapse rate: G1 52%, G2 14%, G3 12% https://t.co/xe6NLVxUov
sheila
1 year ago
COVAD2 data:
⬆️proportion of SLE pts from lmHDI countries were on CS(73% vs 59% p=0.0002), antimalarials(81% vs 68% p=0.0002) & IS(66% vs 53%p=0.0009) vs pts from hvhHDI countries
Comorbids more in younger pts from lmHDI (prob from CS use)
#ACR23 ABST2269 @RheumNow @rheumarhyme https://t.co/4CLGFYG1d0
David Liew drdavidliew
1 year ago
What's the long-term mainentance game plan in IgG4-RD?
WInS IgG4-RD study
China, n=146
IgG4-RD stable disease >12mo
Withdrawing both IM+GC completely has much higher relapse rates vs at least keeping some IM
IgG4-RD needs some steroid-sparing Rx ongoing
#ACR23 L16 @RheumNow https://t.co/1JJpQmFTF5
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
L18 @ #ACR23
⭐️Clinical Implications in Primary Sjögren's Syndrome (pSS) by Molecular classification of Salivary Glands (SGs)
➡️ transcriptomic profiling of SGs in Chinese cohort
👉 396 pSS, 87 non-pSS, & 44 early-pSS
➡️ 3 distinct sub-types:
⭐️Pacui-immune/C1… https://t.co/3ZdrghCB6F https://t.co/hZ9S3hvCzv
Robert B Chao, MD
1 year ago
Withdrawing immunosuppression and steroids in IgG4-RD
Maintaining immunosuppression with or without steroids associated with low relapse rate
52% of pts who withdrew steroids +immunosuppression relapsed
@RheumNow #ACR23 Abs#L16 https://t.co/xJyDiCkMVD
Eric Dein
1 year ago
L17 #ACR23 @RheumNow
Afimetoran TLR7/8 inhib for cutaneous lupus
Safety: No SAEs, mild-mod AEs, lower than PBO
Nasopharyngitis & bronchitis
Trough concentration consistent from D8 to 113, support 30 mg qd
CLASI change; MCDI 50% Afim v 0% PB, CLASI-50 Afim 50% v 0%
Inhib of IFNGS https://t.co/cKYY6rmIWE
Dr. Rachel Tate
1 year ago
#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
Eric Dein
1 year ago
L19 #ACR23 @RheumNow
Hunter: TLC599 injxn for knee OA
Liposomal formulation of dexamathasone sodium phosphate
Improved WOMAC Pain, Fxn, and Aver Daily Pain
Separation of ADP at wk 12 through wk 24
2nd injxn at wk 24 - further benefit
@AusRheum https://t.co/PP7lEsclIc
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
L19 @ #ACR23
⭐️Is sustained relief of OA pain in knee possible with an intraarticular injection?
⭐️TLC599 = liposomal formulation of dexamethasone sodium phosphate (DSP) that can be injected locally
➡️ phase III study assessing efficacy + safety of TLC599 in single or repeat… https://t.co/mQtuhKI52j https://t.co/reswM09VCl
Richard Conway
1 year ago
Spencer-Green et al. IA TLC599 (liposomal dexamethasone) in knee OA. Injection baseline and week 24. Both assoc improved symptoms. As always, look at that placebo injection response! Abstr#L19 #ACR23 @RheumNow https://t.co/oYtkYVboKu https://t.co/RweDRdSieQ
Poster Hall